Carmot Therapeutics

About:

Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.

Twitter/X: CarmotTx

Top Investors: National Science Foundation, Franklin Templeton, RA Capital Management, The Column Group, Deep Track Capital

Description:

Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases. They employ their patented technology, chemotype evolution, to address the fundamental causes of disease and speed the discovery of disease-modifying therapies.

Total Funding Amount:

$385M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Berkeley, California, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)carmot.us

Founders:

Daniel A. Erlanson, Stig Hansen

Number of Employees:

11-50

Last Funding Date:

2023-05-25

IPO Status:

Private

Industries:

Biotechnology

Health Care

Therapeutics